Current State and Future Prospects of Diagnosis and Management of <i>TP53</i>-Mutated Myeloid Neoplasms
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current State and Future Prospects of Diagnosis and Management of <i>TP53</i>-Mutated Myeloid Neoplasms
Authors
Keywords
-
Journal
PATHOBIOLOGY
Volume -, Issue -, Pages 1-10
Publisher
S. Karger AG
Online
2023-10-14
DOI
10.1159/000534566
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MOLECULAR CHARACTERIZATION OF MUTANT TP53 ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME
- (2022) Tim Grob et al. BLOOD
- Time to blur the blast boundaries
- (2022) Courtney D. DiNardo et al. CANCER
- TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia
- (2022) Mehrnoosh Tashakori et al. BLOOD
- Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel
- (2022) Hartmut Döhner et al. BLOOD
- International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data
- (2022) Daniel A. Arber et al. BLOOD
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
- (2022) Joseph D. Khoury et al. LEUKEMIA
- Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
- (2022) Daniel A. Pollyea et al. CLINICAL CANCER RESEARCH
- Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
- (2022) Naval Daver et al. BLOOD
- Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
- (2021) David A. Sallman et al. JOURNAL OF CLINICAL ONCOLOGY
- Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
- (2021) Thomas Cluzeau et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
- (2021) Matteo Molica et al. Frontiers in Oncology
- Distinguishing AML from MDS: A fixed blast percentage may no longer be optimal
- (2021) Elihu H Estey et al. BLOOD
- Outcomes of TP53 ‐mutant acute myeloid leukemia with decitabine and venetoclax
- (2021) Kunhwa Kim et al. CANCER
- Outcomes in patients with newly diagnosed TP53 ‐mutated acute myeloid leukemia with or without venetoclax‐based therapy
- (2021) Sangeetha Venugopal et al. CANCER
- AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results
- (2021) David Sallman et al. Clinical Lymphoma Myeloma & Leukemia
- The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
- (2020) David A Sallman et al. BLOOD
- The CD47-SIRPα Immune Checkpoint
- (2020) Meike E.W. Logtenberg et al. IMMUNITY
- Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
- (2020) Sayantanee Dutta et al. Cancers
- TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
- (2020) David A. Sallman et al. BLOOD
- Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
- (2020) Elsa Bernard et al. NATURE MEDICINE
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
- (2020) Courtney D DiNardo et al. Lancet Haematology
- Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
- (2020) Nicholas J. Short et al. Blood Advances
- TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
- (2019) Detlef Haase et al. LEUKEMIA
- Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment
- (2019) Xufeng Chen et al. Cancer Discovery
- The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells
- (2019) Tamilla Nechiporuk et al. Cancer Discovery
- Synergistic effects of PRIMA-1Met (APR-246) and Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
- (2019) Nabih Maslah et al. HAEMATOLOGICA
- A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
- (2019) Steffen Boettcher et al. SCIENCE
- An Update on Immunotherapy for Solid Tumors: A Review
- (2018) Toan Pham et al. ANNALS OF SURGICAL ONCOLOGY
- A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation
- (2018) Eran Kotler et al. MOLECULAR CELL
- Functional genomic landscape of acute myeloid leukaemia
- (2018) Jeffrey W. Tyner et al. NATURE
- Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
- (2017) Kanaga Sabapathy et al. Nature Reviews Clinical Oncology
- TP53mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes
- (2016) Tapan M. Kadia et al. CANCER
- TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data
- (2016) Liacine Bouaoun et al. HUMAN MUTATION
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
- (2015) D A Sallman et al. LEUKEMIA
- Clinical and biological implications of driver mutations in myelodysplastic syndromes
- (2013) E. Papaemmanuil et al. BLOOD
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Multiple Functions of BCL-2 Family Proteins
- (2013) J. M. Hardwick et al. Cold Spring Harbor Perspectives in Biology
- Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
- (2012) Sören Lehmann et al. JOURNAL OF CLINICAL ONCOLOGY
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Frequent pathway mutations of splicing machinery in myelodysplasia
- (2011) Kenichi Yoshida et al. NATURE
- Clinical Effect of Point Mutations in Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of p53 in Cell Death and Human Cancers
- (2011) Toshinori Ozaki et al. Cancers
- PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
- (2009) L. Zhang et al. BLOOD
- PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
- (2009) Jeremy M.R. Lambert et al. CANCER CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Dysregulated gene expression networks in human acute myelogenous leukemia stem cells
- (2009) R. Majeti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started